Hearscape
← Therapeutics
Details checkedStatus confirmedHistorical/discontinuedCheckedcompany

OTO-6XX by Otonomy

Also known as: OTO-6XX

Otonomy

Primary source
Company
Otonomy
Program Type
Therapeutic
Modality
Regenerative Medicine
Stage
Preclinical
Status
Discontinued
Target Gene
—
Route / Mode
Intratympanic injection
Confidence
84%
Status Confidence
Status confirmed
Evidence Strength
Needs more support
Last Reviewed
2026-05-31
Geography
United States, Japan
Population
adult, age-related, noise-induced
Trial IDs
0
Mechanism

Local small-molecule regenerative program intended to repair or regenerate cochlear hair cells damaged by noise, aging, or ototoxic chemicals.

Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing LossNoise-Induced Hearing LossCisplatin-Induced Hearing Loss
Notes

Important historical regenerative-hair-cell program in the Otonomy portfolio; Otonomy licensed the lead compound from Kyorin before the program disappeared in the company shutdown.

Evidence & Sources
2 structured sources
company
Supports: canonicalName, company, mechanism, indications, stage, route
IDs: OTO-6XX
Open
company
Supports: allCompanies, notes
IDs: OTO-6XX
Open
Key Events
2020-08-03
Otonomy announced a license agreement with Kyorin for the OTO-6XX hearing-loss program
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2